SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?


To: Henry Niman who wrote (15009)2/13/1998 4:01:00 PM
From: David Bogdanoff  Read Replies (1) | Respond to of 32384
 
HN:

>>one of the reasons that Ligand began its diabetes trials in Europe was the European regulatory agency's willingness to allow LGND to start at the Phase II level in the new patient population <<

Thank you for your post which includes the above statement which underscores the point I made.

David